Microembed Pharmaceuticals IVS

Q: What is the CVR number of Microembed Pharmaceuticals IVS?

Microembed Pharmaceuticals IVS is registered with CVR / Virk under CVR 38203312.

Q: How many employees does Microembed Pharmaceuticals IVS have?

Microembed Pharmaceuticals IVS employs 1 people as of the latest annual report.

Q: Where is Microembed Pharmaceuticals IVS headquartered?

Microembed Pharmaceuticals IVS's registered address is Camilla Nielsens Vej 1, 5. th.

IVSDissolvedAdvertising protection

CVR 38203312Camilla Nielsens Vej 1, 2000 FrederiksbergManufacture of pharmaceutical preparations· NACE 2120Est. 2016 · 9 years old1 employees

Overview

Microembed Pharmaceuticals IVS is a Danish IVS based in Frederiksberg, operating in the Manufacture of pharmaceutical preparations sector. Incorporated in 2016, the company has 1 employee and reported a gross profit of -DKK 5.5k in its latest annual filing.

Gross profit 2018

-5.5K DKK

−102% vs 2017

EBITDA margin (of gross profit)

100.0 %

−120% vs 2017

Net profit 2018

-5.9K DKK

-132% vs 2017

Key ratios

See full ratios →

48.5 %

Average

Around the average of companies in the same industry

20172018

1.9×

Average

Around the average of companies in the same industry

20172018

-22.8 %

Very weak

Among the 20% lowest rated companies in the industry

20172018

EBITDA — year on year

DKK thousands

Key figures

Annual report 2018

Gross profit	-5.5K DKK	-102%
EBITDA	-5.5K DKK	-120%
Net profit	-5.9K DKK	-132%
Total assets	25.8K DKK	-64%
Equity	12.5K DKK	-32%
Employees	1	—

Contact

Address

Camilla Nielsens Vej 1, 2000 Frederiksberg

Advertising protection

Active — opted out of marketing use

Risika for professionals

Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.

Visit risika.com

Financial development

In its most recent annual report (2018), Microembed Pharmaceuticals IVS reported a gross profit of -DKK 5.5k, a decrease of 102% on the year before. The figures on this page draw on 2 annual filings covering 2017 to 2018. The bottom line showed a net loss of DKK 5.9k.

At the end of 2018, equity financed 48.5% of the balance sheet, and current assets covered short-term debt 1.9 times.

Financials

Gross profit

DKK thousands

EBITDA

DKK thousands

Income statement

DKK thousands

Item	2018	2017
Gross profit	-5	252
Staff expenses	-0	-225
EBITDA	-5	27
Depreciation & amort.	-0	-0
EBIT	-5	27
Net financials	-0	-3
Profit before tax	-6	24
Tax	-0	5
Net profit	-6	18

Get a credit rating – not just the numbers

Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.

See the credit rating

Balance sheet

DKK thousands

Item	2018	2017
Total assets	26	71
Equity	13	18
Long-term debt	0	0
Short-term debt	13	52
Total debt	13	52

Financial ratios

5-year trend

EBITDA margin (of gross profit)

<−999 %

20172018

Equity ratio

48.5 %

Average

Around the average of companies in the same industry

20172018

Return on equity

-47.0 %

Very weak

Among the 10% lowest rated companies in the industry

20172018

Net profit margin (of gross profit)

<−999 %

20172018

Asset turnover (of gross profit)

-0.21×

20172018

Debt / equity

1.06×

Average

Around the average of companies in the same industry

20172018

Sector performance

22 of 28 ratios graded

28 financial ratios from the latest filing, each graded against companies in the same industry.

Profitability

Return on equity (ROE)Very weak

Among the 10% lowest rated companies in the industry

Net profit as a percentage of equity — the return the owners earned on their invested capital this year.

Return on assets (ROA)Very weak

Among the 20% lowest rated companies in the industry

Net profit as a percentage of total assets — the return generated on the capital employed.

Return on net assets (RONA)Very weak

Among the 10% lowest rated companies in the industry

Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.

Basic earning power (BEP)Very weak

Among the 20% lowest rated companies in the industry

EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.

Gross marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.

Operating marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.

Net profit marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The profit for the year as a share of revenue — the company's ability to turn revenue into profit.

Capacity ratioNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.

Liquidity

Current ratioAverage

Around the average of companies in the same industry

Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.

Quick ratioStrong

Among the 40% highest rated companies in the industry

Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.

Cash ratioVery strong

Among the 20% highest rated companies in the industry

Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.

Current assets to equityWeak

Among the 30% lowest rated companies in the industry

Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.

Fixed assets to long-term capitalVery strong

Among the 10% highest rated companies in the industry

Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.

Cash conversion ratioWeak

Among the 30% lowest rated companies in the industry

Cash flow relative to profit — the ability to convert reported profits into accessible cash.

Debt & solvency

Solidity ratioAverage

Around the average of companies in the same industry

Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.

Debt ratioAverage

Around the average of companies in the same industry

Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.

Debt to equityAverage

Around the average of companies in the same industry

Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.

Liabilities to equityAverage

Around the average of companies in the same industry

Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.

Income to debtVery weak

Among the 20% lowest rated companies in the industry

Profit relative to debt — the ability to create earnings while operating with debt.

EBITDA to debtVery weak

Among the 20% lowest rated companies in the industry

EBITDA relative to debt — how much operating earnings are available to service the debt.

Interest coverageVery weak

Among the 20% lowest rated companies in the industry

The ability to pay the interest on the company's debt out of its earnings.

Interest rate on debtStrong

Among the 40% highest rated companies in the industry

Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.

Interest marginWeak

Among the 30% lowest rated companies in the industry

The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.

Efficiency & development

Equity to contributed capitalVery strong

Among the 10% highest rated companies in the industry

Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.

One-year change in equityVery weak

Among the 20% lowest rated companies in the industry

The size of this year's increase or decrease in the company's equity.

One-year change in debtVery strong

Among the 10% highest rated companies in the industry

The size of this year's increase or decrease in the company's debt.

Asset turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to total assets — the ability to generate revenue from the asset base.

Inventory turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.

Annual reports & filings

Annual report 2018
Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
View PDF
Annual report 2017
Filed via CVR / Virk · Period 2016-11-18 – 2017-12-31
View PDF

People & ownership

Management

Actively employed in the business

Name	Role	Member since

Former (2)


AJ Adam Jun Bohr Management	Management	2016 – 2019
JJ Jorrit Jeroen Water Founder	Founder	2016 – 2019

Board of directors

Non-executive oversight

No data on file.

Shareholders

Active legal owners

Shareholder	Type	Ownership	Votes	Registered
Adam Jun Bohr	Individual	50–66.65%	50–66.65%	2016
Jorrit Jeroen Water	Individual	50–66.65%	50–66.65%	2016

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.

One in three Danish companies experiences fraud

Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.

See the fraud module

Related companies

Company hierarchy

No registered parent or subsidiaries

Board network connections

Board members of Microembed Pharmaceuticals IVS also hold positions in 5 other companies.

Person	Role here	Other companies
Jorrit Jeroen Water	Founder	3 companies
Adam Jun Bohr	Management	2 companies

Frequently asked questions

What is the CVR number of Microembed Pharmaceuticals IVS?

Microembed Pharmaceuticals IVS is registered with CVR / Virk under CVR 38203312.

What is the gross profit of Microembed Pharmaceuticals IVS?

Microembed Pharmaceuticals IVS reported a gross profit of -DKK 5.5k in 2018.

How many employees does Microembed Pharmaceuticals IVS have?

Microembed Pharmaceuticals IVS employs 1 people as of the latest annual report.

Where is Microembed Pharmaceuticals IVS headquartered?

Microembed Pharmaceuticals IVS's registered address is Camilla Nielsens Vej 1, 5. th.